I don’t have any resolutions for 2026. I’ll touch on 2025, but I’m not here to dissect 2025. Rather, I’m working on living with a

-The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 in

The Peterson Health Technology Institute outlined five key recommendations for employers seeking to design sustainable GLP-1 coverage. The post PHTI: How Employers Can Manage GLP-1

The main question on Wall Street these days is whether the bull run will continue in 2026. For 2023, 2024, and 2025, the S&P 500’s

Glucagon-like peptide 1 (GLP-1) is secreted from the intestinal L cells in a glucose-dependent manner. However, the mechanism underlying how glucose stimulates the secretion remains

Across the U.S., a new and controversial cosmetic trend called AlloClae is gaining traction, which utilizes purified fat from donated cadavers to enhance the body

PNW sets MLK Day events Purdue University Northwest has scheduled celebrations of the Rev. Martin Luther King Jr.’s life and legacy through free programming on

The nutritional expert spoke out as more and more of us start using GLP-1 medications

I lied repeatedly throughout my online application for a GLP-1 medication, convinced that – at some point – I would be face a medical provider

I’ll teach you how to become the media’s go-to expert in your field. Enroll in The Professional’s Media Academy now: https://www.professionalsmediaacademy.com/ Listen to my podcast,

Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under

Pharmaceutics, Vol. 18, Pages 69: Liraglutide and Exenatide in Alzheimer’s Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes Pharmaceutics doi:

Brian Lian founded publicly traded Viking Therapeutics to focus on metabolic diseases. With obesity drugs in development and the GLP-1 space booming, it’s now a

Many people who successfully lost weight on Ozempic and other GLP-1 agonist drugs are having trouble weaning themselves off the injectables, according to the BBC, because

Metabolites, Vol. 16, Pages 45: A Comprehensive Review on Medium- and Long-Chain Fatty Acid-Derived Metabolites: From Energy Sources to Metabolic Signals Metabolites doi: 10.3390/metabo16010045 Authors:

Diageo (LSE: DGE) shares have experienced an unbelievable price fall over the last few years. Currently, theyâre trading about 55% below their highs. Could they

Hangzhou-based biotech start-up MindRank has progressed to Phase 3 clinical trials for its weight-loss drug, making it China’s first artificial intelligence-assisted Category 1 new drug

Most people focus on what they eat, but very few realize that the order you eat your food can dramatically change how your body responds.

From bunless burgers to cups filled with meat, fast food chains are reshaping their menus as weight-loss drugs and wellness trends change how Americans eat.

(MedPage Today) — In January 2025, we reported about an observational study of nearly 2 million U.S. military veterans that showed a broad spectrum of

Semaglutide patent expiries in India, Canada, and Brazil are poised to unlock over Rs 50 billion in revenue for generic drugmakers within 12-15 months. Indian

Fractyl Health, Inc. (NASDAQ:GUTS) is one of the 10 Best New Penny Stocks to Invest In. On December 19, Canaccord Genuity reiterated its Buy rating

An often-overlooked part of the body may reveal important clues about overall health. Researchers from the University of Westminster in the U.K. discovered that the

Post Content

Over the past year, the best-performing S&P 500 sector was communication services, followed by information technology. This might not surprise some, but with us now

Obesities, Vol. 6, Pages 1: The Interplay Between Insulin Resistance, Affective Dysregulation, and Binge Eating in Obesity: Toward an Integrated Biopsychosocial Treatment Model Obesities doi:

Post Content

Frazer Harrison / Getty Images Demi Lovato, 33, posted a year-end roundup of photos to Instagram, captioning the carousel of 16 snapshots “unseen (little) bits

Key Points Pfizer’s oncology ambitions could start to take shape next year. The drugmaker is also likely to make progress in the weight-loss market. It

Jelly Roll is crediting his weight loss for improving his sex life with wife Bunnie Xo. “My testosterone level — and I’m cool to talk

A review of 2025’s noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.

PILLARS OF HEALTH — 6 tips to extend longevity in the new year, according to experts WEIGHT-LOSS WAVE — Oprah joins wave of celebrities who

21st Century Wire NEW YEAR SPECIAL Looking forward into the New Year, here are some predictions and trends to keep an eye out for. This

Getty Rapper Jelly Roll, 41, has revealed that he lost 275 pounds without the use of GLP-1 medications. Instead, the Grammy nominee focused on rewiring

Jelly Roll is sharing new details about his weight loss. Over the past two years, the 41-year-old country music singer has been on a weight

For drugs that are in such hot demand and have such large cultural and economic effects, you might expect the mechanism would be more widely

A company is looking for a Collaborating Physician to support its clinical team. Key Responsibilities Serve as a collaborating physician for NPs practicing within the

Welcome to a new year! And to this week’s Food Exec Brief, your strategic intelligence roundup covering AI’s transition from experiment to infrastructure, the agricultural

GLP-1 weight loss drugs such as Ozempic and Wegovy have taken the world by storm. But some side effects, from the accepted – ‘Ozempic face’

Shake Shack introduces new GLP-1 menu options